6931 Arlington Rd #400, Bethesda, MD 20814, United States

  • Phone:+1 301-656-1080

Freedom
That Feels Real

With Bronchitol, living with cystic
fibrosis does not mean living with limits.

*The image is not to scale.

A mucoactive agent* that fits into patients’ lives

*The precise mechanism of action of BRONCHITOL in improving pulmonary function in cystic fibrosis (CF) patients is unknown.

BRONCHITOL is not intended to be used as a rescue medication. Inhaler and blister pack are not actual size and are for representation only.
Patients prescribed Bronchitol also need to take an inhaled bronchodilator 5 – 15 minutes taking their daily Bronchitol dose (morning and evening).

BRONCHITOL® (mannitol) inhalation powder—the first and only dry powder inhaled mucoactive agent* for patients with CF

The BRONCHITOL inhaler is:

Compact, handheld

Discreet

Portable

BRONCHITOL requires no:

Nebulization

Refrigeration

Routine maintenance

BRONCHITOL dosing and administration

BRONCHITOL is not intended to be used as a rescue medication. Patients prescribed Bronchitol also need to take an inhaled bronchodilator 5 – 15 minutes taking their daily Bronchitol dose (morning and evening).

How to Administer
dosing3
Component 20

BRONCHITOL improves FEV1

Patients taking BRONCHITOL experienced sustained improvements in FEV1 vs control over 26 weeks.1

Review the clinical data

Consider these potential BRONCHITOL patients

Review profiles of potential patients for whom BRONCHITOL may be appropriate.

See the profiles
patient-p

Important Safety Information

BRONCHITOL is contraindicated in patients with hypersensitivity to mannitol or to any of the capsule components. BRONCHITOL is contraindicated in patients who fail to pass the BRONCHITOL Tolerance Test (BTT).

BRONCHITOL can cause bronchospasm, which can be severe in susceptible patients. Because of the risk of bronchospasm, prior to prescribing BRONCHITOL, patients must pass the BRONCHITOL Tolerance Test (BTT). The BTT must be administered under the supervision of a healthcare practitioner who can treat severe bronchospasm.

Patients who pass the BRONCHITOL tolerance test (BTT) may experience bronchospasm with add-on maintenance therapy with BRONCHITOL. Patients should premedicate with an inhaled short-acting bronchodilator prior to each administration of BRONCHITOL. If bronchospasm occurs, immediately discontinue BRONCHITOL and treat bronchospasm with an inhaled short-acting bronchodilator.

Hemoptysis can occur with BRONCHITOL use. Monitor patients with history of episodes of hemoptysis. If hemoptysis occurs, discontinue use of BRONCHITOL.

Most common adverse reactions (≥3%) include cough, hemoptysis, oropharyngeal pain, vomiting, bacteria sputum identified, pyrexia, and arthralgia.

Please see Full Prescribing Information.

Indication

BRONCHITOL® (mannitol) inhalation powder is a sugar alcohol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use BRONCHITOL only in adults who have passed the BRONCHITOL Tolerance Test.

Reference: 1. BRONCHITOL® (mannitol) inhalation powder Prescribing Information. 2024.